New Key Statistics Module, Z-Score and F-Score
NAS:SYRS Key Ratios
| Market Cap $ M | 44.50 |
| Enterprise Value $ M | 26.20 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | 11.29 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 4.00 |
| EPS (TTM) $ | -4.34 |
| Beneish M-Score | -4.39 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 23.10 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.21 |
| EV-to-EBITDA | -0.21 |
| PEG | -- |
| Shares Outstanding M | 26.81 |
| Net Margin (%) | -3,171.70 |
| Operating Margin % | -2,835.68 |
| Pre-tax Margin (%) | -3,171.70 |
| Quick Ratio | 3.46 |
| Current Ratio | 3.46 |
| ROA % (ttm) | -89.09 |
| ROE % (ttm) | -487.60 |
| ROIC % (ttm) | -324.23 |
| Dividend Yield % | -- |
| Altman Z-Score | -12.79 |
SYRS Number of Guru Trades
SYRS Volume of Guru Trades
Gurus Latest Trades with NAS:SYRS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:SYRS is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Syros Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:SYRS
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers